Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
about
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisPersonalized treatment for advanced colorectal cancer: KRAS and beyondRandomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.Evolution of systemic therapy for advanced pancreatic cancer.Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study.Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyPrognostic and predictive response factors in colorectal cancer patients: between hope and reality.Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.New trends in epidermal growth factor receptor-directed monoclonal antibodies.Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyFinal results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.Rash rates with egfr inhibitors: meta-analysis.Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multiMuscarinic receptor agonists stimulate human colon cancer cell migration and invasion.A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials.Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.Therapeutic antibodies against cancer.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study.Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancerTargeted therapies in colorectal cancer-an integrative view by PPPMMammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.Optical molecular imaging and its emerging role in colorectal cancer.Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.Personalized medicine - the promised land: are we there yet?Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.Panitumumab: a summary of clinical development in colorectal cancer and future directions.Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.Panitumumab in metastatic colorectal cancer.Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.Panitumumab : leading to better overall survival in metastatic colorectal cancer?An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
P2860
Q26777704-C2362739-6AB7-4A7F-A919-2D7F8A7E5D03Q26822817-B950BDE7-FC21-4091-8EF3-14ED99EAD79CQ33391425-20901AD2-D00F-4CFA-8C18-885433120569Q33557413-E71245AC-73C7-4727-AC06-4955F1EB69E9Q33816064-4A802B23-D760-4F8A-9646-02D3BB11CCD1Q33840094-043374FA-8CC5-40B3-AA57-5FEDA48217B1Q33916016-A4D106A8-E3EF-43B0-9521-2734F70C1912Q34239801-5187424C-D8FE-4538-B66A-A4C110728AC0Q34424047-B0357143-420E-4645-B4B3-9C0573BF7DF7Q34467133-133C7861-F068-44F3-B118-3150A870D115Q34508065-3397D73A-4603-479B-9B06-DA2F54338F8BQ34621577-AF579140-B50F-43AD-8C7F-B33F528ABEF1Q34658247-DE4EF21D-71B6-4E69-8617-7F4C8C354855Q34658519-481DEB6D-36D8-4A17-9873-DCE4AC6A3467Q34761646-E342176E-3C47-463D-874A-9914CD117860Q34820775-43142F9C-02E3-4B13-B56A-2C13A82ECEF9Q34979987-C10329CD-3678-4950-BB5E-9F108AAD8806Q35034768-1DCF4CA7-C0FA-47CD-8E67-7803C033DF7CQ35211367-533D3FEA-E1A7-498E-8A8D-B21E3E3EF0EEQ35584416-17C14143-21BA-41A4-AA01-09E23B41ED71Q35655093-4236BB83-526B-46EB-BC6E-D9C52F6F1A0BQ35908498-7B867804-F7C6-46F5-A110-A40653E20352Q35913241-0FD03BE4-57CD-4B4D-8097-BA3C0019E556Q36232353-58A77E20-6AD9-4CCC-B359-7F80D3362398Q36621776-C6445629-DF43-40D7-9956-2E8A553CF45DQ36646911-856421A7-301C-4DC8-89C1-8C7266DCA07DQ37621799-191A161A-9BD9-4549-9106-BF39317229A2Q37769375-4A3A4623-5698-4AC9-B926-EABC9FD26210Q37780040-7A984212-2B54-4F12-AA2C-C548B833C223Q37825915-DDF28902-8CA4-483F-B83E-83CF1D232079Q37916396-34089042-A6D7-4D00-8A8F-1A23917CCB6DQ37987802-618154E0-0377-418C-B48B-16EF3D2CB15CQ38003666-DAC86F5B-6E65-4F99-983F-435014F870E4Q38090584-FB4736D9-9088-47B0-9908-15F93705E473Q38117191-229B8D00-A53F-456C-AD2D-AF5DE5F93527Q38175030-C907AEF8-EBC9-4117-AEEC-1ED1D2154EDBQ38193195-25378DCC-39F4-4A3C-94F4-C3DD73AA64FCQ38432573-7489417C-1711-4AE2-952E-E6677E049337Q38650454-EF8DD14E-DD27-40B9-A0F4-EB469419F0CCQ38666172-CA570831-6728-4888-94D3-DB9C5DCDB461
P2860
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Association of progression-fre ...... iving panitumumab monotherapy.
@en
Association of progression-fre ...... iving panitumumab monotherapy.
@nl
type
label
Association of progression-fre ...... iving panitumumab monotherapy.
@en
Association of progression-fre ...... iving panitumumab monotherapy.
@nl
prefLabel
Association of progression-fre ...... iving panitumumab monotherapy.
@en
Association of progression-fre ...... iving panitumumab monotherapy.
@nl
P2093
P50
P356
P1433
P1476
Association of progression-fre ...... eiving panitumumab monotherapy
@en
P2093
Alain Hendlisz
Alberto Sobrero
Eric Van Cutsem
Giovanna Devercelli
Michael Wolf
Rafael G Amado
P304
P356
10.1002/CNCR.24088
P407
P577
2009-04-01T00:00:00Z